skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

New treatment options for lupus – a focus on belimumab

Review

(1298) Views  (568) Full article downloads

Authors: Chiche L, Jourde N, Thomas G, Bardin N, Bornet C, Darque A, Mancini J

Published Date January 2012 Volume 2012:8 Pages 33 - 43
DOI: http://dx.doi.org/10.2147/TCRM.S19819

Laurent Chiche1,2, Noémie Jourde3, Guillemette Thomas1, Nathalie Bardin2, Charleric Bornet4, Albert Darque4, Julien Mancini5
1Department of Internal Medicine, Centre de Compétence Maladies Auto-immunes Systémiques PACA Ouest, 2Laboratory of Immunology, 3Department of Nephrology, 4Department of Pharmacy, Hôpital de la Conception, Marseille; 5Department of Public Health, Hôpital de la Timone, Marseille, France

Abstract: Belimumab is the first biologic approved for patients with systemic lupus erythematosus (SLE). Belimumab is the first of a new class of drug targeting B cell-stimulating factors or their receptors to reach the market. Its target, BLyS, also known as BAFF (B cell-activating factor from the tumor necrosis factor family), is a type II transmembrane protein that exists in both membrane-bound and soluble forms. Additionally to a robust rational from murine experiments conducted in lupus prone mice, BLyS circulating levels are increased in SLE patients. After the negative results of a Phase II trial, two Phase III trials met their primary endpoints. Some SLE patients are still refractory to the standard options of care or necessitate prolonged high-dose corticotherapy and/or long-term immunosuppressive regimens. However, some experts still feel that the effect of this biologic might not be clinically relevant and blame the use of the new systemic lupus response index as well as the discrepancies between both trials and the noninclusion of the severe form of the disease as nephritis. In this review, we aim to discuss the characteristics of belimumab, critically evaluate the different steps of its development, and consider its future place in the arsenal against SLE, taking into account the patients’ perspectives.

Keywords: systemic lupus erythematosus, belimumab, treatment, monoclonal antibodies, adverse effects, BLyS







Readers of this article also read:

An update on belimumab for the treatment of lupus
Clinical utility of adjunctive retigabine in partial onset seizures in adults
Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility
Coronary artery disease in Africa and the Middle East
Noninvasive radioelectric asymmetric conveyor brain stimulation treatment improves balance in individuals over 65 suffering from neurological diseases: pilot study
Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus
Ruxolitinib for the treatment of myelofibrosis: its clinical potential
Human normal immunoglobulin in the treatment of primary immunodeficiency diseases
Optimal management of giant cell arteritis and polymyalgia rheumatica
NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab